# Genmab’s latest phase 2 data spur claim ADC is ‘clearly superior’ to AbbVie’s Elahere

> **Newsylist Open Intelligence Dossier** · First detected: 2026-10-05 21:29 UTC · Category: Business · Sources: 5 · Current Velocity: 2.8

## Key People, Organizations & Locations
ADC, AbbVie, Genmab, Elahere

## Multi-Source Evidence Table
| Source Outlet | Headline | Published (UTC) | Verification URL |
|---|---|---|---|
| Endpoints News | Genmab details ovarian cancer data; Lilly’s Jaypirca gets a label expansion | 2026-10-05 08:14 | [Source Link](https://news.google.com/rss/articles/CBMingFBVV95cUxOQTZZMzlkb1dNZmRlSC1zWU9UVzZJNVozMHYwOFRVSGl3RF9PcU03dDd6bE92VmVYY3B2Wk9UV1dwYklFQm1qSkVIMzNmTFRsT3poN1B3UlJRUUljRHIzc0dRR3RsY2N0MENZd3JVTzlQZm8xTUxlUnNBdllZT081YzMtczZodjhFakhuNVFuaFFwcG85Y0lXMkh3Z3psQQ?oc=5) |
| The Pharma Letter | Genmab’s Rina-S shows durable responses in ovarian cancer | 2026-10-05 08:14 | [Source Link](https://news.google.com/rss/articles/CBMiowFBVV95cUxOQlpLUTJTYWhxQmM5ZXVHTkp2WDhvVlRZTkhPazh6T2J2U2V5MEdGRHZpNEtkMWhQQXQyS3dWbjZ4YWxNRl9LSnc2ZmEwbFJ0TFNXTXRNV1Z1NTdLTU1wbUliSVF6OC1hU2ltVERkTnNabTMtcnNrZENlUk1hMTJ3LUp2RWxZSGN2ZE1BNWc2aW5KdjdHTkduSExvQVcyenBwcWdZ?oc=5) |
| European Biotechnology Magazine | Genmab’s Phase 2 data strengthens case for $1.8B ProfoundBio bet | 2026-10-05 08:14 | [Source Link](https://news.google.com/rss/articles/CBMirwFBVV95cUxNeF9BeVlEUXBKV0ZrekdhY2l0Tzctc3pIcWF2c0lGdEh3NHI0VlJhV0xKRms5b1VJN1RkMzd0TWREQWVoSzFXbkJqZ2lMb1otZTJBZnNzMmJtWTVHVHBJX2d5V0llZW9OclBjTGZzbDdlTU94RXFVU2dBVjhBbU5oWEhpQzl1bWVUalRya3Eza1ROOUFTTUxpQUFFamozRkhpS1J1QzdhaGFJbFhJTVhj?oc=5) |
| Business Wire | Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer | 2026-10-05 08:14 | [Source Link](https://news.google.com/rss/articles/CBMi1wJBVV95cUxOb0RfRzlGOUdMSGY2S1pkXzlXS3ZJRm1fWlJrWDhIUnA4WjQ5Y3VLbm80eEhiRmo4QzZJaW81V3NJWE9nbGZiYm5yUGZUUkdNQ3VQZ3ZFMHU0ZGZKdndlb3g3VThqSHBVb3h0Y2I1MnFMX00yRzhiSW1NZUJHdHVLQUczM21NZlJ2clVVLWxpLW1zUWV1eC03QWRKV2xhMWVZNHlfeTJ3cm9iSmV0MkRJeDduZjMtUG1DYVZ3SFBsUWV5MmZCYlRvRkFGbGcxRWl2VHZjVWxVZGYzck1xY3VDdVJHNGgyTmxyVXlELVNJUFRnd0FzUFc5M2YwMS1Cdlc0S3FNczMwSV9IX3F0RkpCQ0RFTTVoQXZGV19XOUxsNGpsMGdjOThTYi1IcHdZWng3THhhOHQtU3dWNDI5Zl9sSGN2UTFzZWxLUURFZS1PaG5KRy1SbHJ) |
| Fierce Biotech | Genmab’s latest phase 2 data spur claim ADC is ‘clearly superior’ to AbbVie’s Elahere | 2026-10-05 08:14 | [Source Link](https://news.google.com/rss/articles/CBMingFBVV95cUxNaVVhNWU5c3BuNjJkdnpGMGEtcUV1ZjNFcG92ZnZCM2R6SE42VDJPSUhpcTVLZmY1UHdBWjBsWktlVUc0ZnZOQzYwNDEzbEFvanZNVFE3SVdFSjZJMVh5SGxiaHViQTYzLWxUWEdiWVJOT2h4eGhnek1fZ1RrV1o2ZXlBdVJ2YzhFejlEaDJhWFVCdml1M2czN1hIYjlzUQ?oc=5) |

---
*Canonical Source: https://www.newsylist.com/trend/2026-10-05/genmab-s-latest-phase-2-data-spur-claim-adc-is-clearly-superior-to-abbvie-s*
*Synthesized by Newsylist Open Intelligence Engine under E-E-A-T journalistic standards.*